NetworkNewsBreaks Archive - Page 2007 of 2085

MondayApr 17, 2017 11:55 am

NetworkNewsBreaks – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) Fails To Meet Endpoints in Phase 2 Trial of Tarextumab; Discontinues Enrollment in Brontictuzumab Trial

OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) shares are down 19% after the company reported top-line results from the phase 2 PINNACLE clinical trial of tarextumab in previously untreated patients with extensive-stage small cell lung cancer. The combination of tarextumab plus chemotherapy results were undifferentiated from those of chemotherapy plus placebo, which means the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation. Additionally, the company said it is discontinuing enrollment in the phase 1b clinical trial of brontictuzumab in combination with trifluridine/tipiracil in third-line colorectal cancer…

MondayApr 17, 2017 11:38 am

NetworkNewsBreaks – Westport Fuel Systems (NASDAQ: WPRT) Signs Definitive Agreement to Sell its APU Assets for $70M; Shares Rally

Westport Fuel Systems (NASDAQ: WPRT) shares jumped 16% this morning after the company said it has entered into a definitive agreement to sell the assets of its Auxiliary Power Unit (APU) business for $70 million. The sale is consistent with the company’s strategy to streamline its business and focus on alternative fuel solutions for the transportation and automotive industries. The transaction is expected to close within a few weeks. "After a careful assessment of the APU product line and its fit with the other Westport Fuel Systems businesses, we decided it made the most sense for our shareholders to pursue…

MondayApr 17, 2017 9:44 am

NetworkNewsBreaks – CytoDyn’s (CYDY) PRO 140 Not Granted Orphan Drug Designation Due to Broad HIV Treatment Potential

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that its application for Orphan Drug Designation for PRO 140 was not granted by the Office of Orphan Products Development of the U.S. Food and Drug Administration. Per the update, the company’s clinical stage monoclonal antibody was deemed to have potential to treat more than just the subset of multi-drug resistant HIV patients for which the designation was requested. CytoDyn is currently conducting multiple Phase 2b/3 trials of PRO 140, including one in combination with other antiretroviral agents in the patient population outlined in the company’s Orphan Drug Designation application, as…

ThursdayApr 13, 2017 1:59 pm

NetworkNewsBreaks – Function(x), Inc. (NASDAQ: FNCX) Receives $3.20 PT from SeeThruEquity

SeeThruEquity has initiated coverage and issued a price target of $3.20 on shares of Function(x), Inc. (NASDAQ: FNCX). The analyst noted that the company’s media properties, Wetpaint and Rant, had approximately 210 million page views in March and have over 10 million social media followers. The analyst also cited the company’s steps to restructure its balance sheet, demonstrated by the $4.8 million new equity capital raised in February. Function(x) is also evaluating the sale of non-core assets and is in the process of renegotiating its debt. For more information, visit www.functionxinc.com About Function(x), Inc. Function(x) operates Wetpaint.com and Rant. Wetpaint…

ThursdayApr 13, 2017 1:57 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Net Element, Inc. (NASDAQ: NETE), Issues $2.45 PT

SeeThruEquity has issued a company update and reaffirmed its price target of $2.45 on shares of Net Element, Inc. (NASDAQ: NETE). Among other highlights, the analyst notes NETE’s full-year 2016 revenue growth of 35% to $54.3 million, driven by strength in its largest segment, North American Transaction, and an increase in the volume of transactions processed on NETE's platform, which rose by 40% versus 2015, to reach $2.45 billion. NETE’s NA Transactions segment consists of Unified Payments, a provider of comprehensive turnkey payment processing solutions, as well as Aptito, a cloud-based restaurant management solution. For more information, visit www.netelement.com About…

ThursdayApr 13, 2017 12:59 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 13, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: FCSC 20.93% – News: Presenting at the 7th Annual World Orphan Drug Congress USA on April 21 KCPC 16.67% – News: Announces publication of results from terminal liver cancer trial QSMG 12.79% – News: Names new CFO STAF 10.99% – News: Posts FY 2016 financial results GTHP 10.20% – News: Ships five LuViva devices to Shandong Yaohua KPAY 9.09% – News: Adds multi-finance companies to platform AVGR 8.94% – News: Provides update EYES 7.85%…

ThursdayApr 13, 2017 12:59 pm

NetworkNewsBreaks – Relmada Therapeutics, Inc.’s (RLMD) d-Methadone Receives Fast Track Designation by FDA; Shares Rise

Relmada Therapeutics’ (OTCQB: RLMD) shares are up 20% mid-day after the company said that it has received Fast Track designation for d-Methadone from the U.S. Food and Drug Administration (FDA) for the adjunctive treatment of major depressive disorder. This designation offers many advantages, including more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of…

ThursdayApr 13, 2017 11:57 am

NetworkNewsBreaks – Intellipharmaceutics International, Inc. (NASDAQ: IPCI) Receives ‘Hold’ Rating, Reduced PT at Aegis Capital

Aegis Capital has issued a ‘Hold’ rating and a lowered price target of $2 on shares of Intellipharmaceutics International (NASDAQ: IPCI). The news follows recent patent litigation from Purdue Pharma against Intellipharmaceutics regarding the New Drug Application (“NDA”) filing for its Rexista™ product candidate. The FDA is stayed for 30 months from granting final approval to the company’s Rexista™ as a result of these legal proceedings, unless a final declaration of the courts is entered that the patents are either invalid or are not infringed, or the matter is otherwise settled among the parties. The analyst noted the patent suit,…

ThursdayApr 13, 2017 11:53 am

NetworkNewsBreaks – Aegis Capital Reiterates ‘Buy’ Rating, $25 PT on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

Aegis Capital Corp. has reiterated a ‘Buy’ rating and $25 price target on the stock of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE). The report follows the unexpected delay of the company’s CTP-543 phase 2a trial for alopecia areata. The delay of one quarter was caused by the tablet being unable to meet release criteria regarding appearance. The analyst noted this delay as insignificant and reiterated the ‘Buy’ rating. For more information visit www.concertpharma.com About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet…

ThursdayApr 13, 2017 11:51 am

NetworkNewsBreaks – SeeThruEquity Issues Updated Coverage on GEE Group, Inc. (NYSE: JOB)

SeeThruEquity has issued an update on shares of GEE Group’s (NYSE: JOB) stock following recent first quarter 2017 financial results, in which the company reported revenues of $22 million, compared to $17.6 million in the first quarter of 2016. GEE Group also recently acquired SNI Companies, a private staffing company with over $100 million in annual revenue. The analyst cited this acquisition as fuel to accelerate the company’s penetration into professional staffing and generate cash flow. For more information visit www.geegroup.com About GEE Group Inc. GEE Group Inc. is a provider of specialized staffing solutions and is the successor to…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks